Company / Profit Margin
KalVista Pharmaceuticals, Inc. Profit Margin History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-364.4%
FY2020
5-year range
-
FY2017-FY2020
Trend
+70.5%
vs FY2019
Sector context
#119 of 145
Health Care
What the data says
KalVista Pharmaceuticals, Inc.'s profit margin of -364.4% is lower than 82% of companies in the Health Care sector (FY2020). Profit Margin returned to growth in FY2020 after 2 years of decline, reaching -364.4%.
Based on SEC 10-K filings.
-364.4% in FY2020 with a 3-year CAGR of -176.1%.
Improved from -536.2% to -364.4% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -176.1pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 145This company -364.4% Sector average -792.7%
▼
+54.0% above sector average
Key checks
Key Insights
- In FY2020, profit margin increased 70.5% year-over-year.
- Currently 428.3pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | -364.4% | +70.5% |
| FY2019 | -1236.9% | -130.7% |
| FY2018 | -536.2% | -184.7% |
| FY2017 | -188.3% | - |
| FY2016 | - | - |
As of FY2020 · SEC 10-K · Updated Jun 30, 2026